A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

Summary

Double-blind, randomized, placebo-controlled study to explore the efficacy and safety of elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or NASH (nonalcoholic steatohepatitis)

Timeline

Start

2019-06-06

Primary completion

2020-06-26

Completion

2020-07-15

Outcome

Met primary endpoint

registry analysis (superiority test); Elobixibat vs Placebo; p = 0.029; LS-Means Difference -0.40 (95% CI -0.76 to -0.04); ANCOVA NCT04006145 ↗

Drugs

Indications